The Weight Loss Shot That Changed Everything (And the Science Behind Why It Works)

In 2021, something unusual happened in American medicine. A drug that had been approved for type 2 diabetes since 2017 — largely unremarkable, used by a few million patients — suddenly became the most talked-about medication in the country.

People started losing 15, 20, sometimes 25 percent of their body weight. The waiting lists grew. Pharmacies ran out. Celebrities stopped mentioning their diets. Hollywood looked different.

The drug was Wegovy. The ingredient was semaglutide. And nothing about weight loss medicine has been the same since.

The Problem It Solved

To understand why semaglutide was such a revelation, you need to understand what obesity medicine looked like before it.

For decades, the diet-and-exercise approach dominated — often accompanied by the implicit (and sometimes explicit) message that people who were obese simply lacked willpower. When drugs were used, they were often stimulant-based — revving up metabolism with compounds that raised heart rate and blood pressure. Several of them were pulled from the market for causing heart problems.

The scientific reality, which had been accumulating in research labs for years, was different: obesity is a disease of dysregulated hormones and brain signaling, not a character flaw. Your appetite, your feeling of fullness, your metabolic rate — these are all tightly controlled by biological systems. And in many people, those systems get set in ways that make maintaining a healthy weight extremely difficult.

Enter GLP-1.

Meet Your Gut Hormone

GLP-1 stands for glucagon-like peptide-1. It's a natural peptide hormone produced in your gut after you eat. When food hits your small intestine, cells there release GLP-1, which does several useful things:

• Tells your pancreas to release insulin (lowering blood sugar)
• Tells your liver to stop releasing glucose
• Slows the movement of food through your stomach (so you feel full longer)
• Travels to your brain and activates receptors that signal: I've had enough

In other words, GLP-1 is your body's built-in appetite brake.

The problem is that natural GLP-1 gets broken down in your bloodstream within minutes. It's a very short-lived signal. Scientists spent years trying to figure out how to make that signal last longer.

What Semaglutide Actually Is

Semaglutide is a synthetic peptide designed to mimic GLP-1 — but with modifications that make it last for weeks instead of minutes. Injected once a week (or taken daily in an oral form), it keeps those appetite-braking signals turned on continuously.

The results in clinical trials were unlike anything obesity medicine had seen. In the STEP trials — the large studies that led to Wegovy's approval — people on semaglutide lost an average of about 15% of their body weight over 68 weeks. People on placebo lost about 2.4%. The gap was enormous.

More importantly, the drug also reduced cardiovascular events in people with obesity and heart disease — cutting heart attacks and strokes. This was announced in 2023 and is a big deal. It means these drugs aren't just helping people look different. They may be saving lives.

What It's Not

With all the hype, some clarifications are necessary.

Semaglutide is not magic. It works best combined with changes to diet and exercise. When people stop taking it, weight tends to return — gradually, over one to two years — because the drug was doing the job of a hormone signal that wasn't working properly. Stopping the drug means losing that signal again.

"Ozempic face" is not caused by semaglutide. The facial changes some people notice are from rapid weight loss, period. Losing weight quickly — by any method — can cause changes in facial volume. Slowing down weight loss (which doctors can manage by adjusting doses) reduces this.

Compounded semaglutide is not identical to brand-name Ozempic or Wegovy. During drug shortages, many compounding pharmacies began making semaglutide, including versions using the "salt form" of the compound rather than the base. These are not the same. Their bioavailability may differ. Quality varies enormously across compounding facilities.

Where Things Stand Today

Semaglutide now has FDA approval for type 2 diabetes (Ozempic), obesity (Wegovy), and cardiovascular risk reduction. It's one of the most thoroughly studied drugs in recent history, with an evidence grade that researchers classify as A — the highest level, based on multiple large randomized controlled trials.

Its close cousin, tirzepatide (Mounjaro, Zepbound), has since arrived and in head-to-head trials produces even greater weight loss on average — about 20% versus 14%. We'll cover that in a future post.

The GLP-1 revolution has only just begun. Researchers are studying these drugs for Alzheimer's disease, alcohol dependence, fatty liver disease, polycystic kidney disease, and more.

Whether semaglutide is right for you is a question for your doctor. But understanding what it is and how it works is the first step to having that conversation clearly.